Noticias y vídeos - INCYTE CORP.

Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”) are pleased to announce that on 31 March 2024, that the...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Wells Fargo 2023 Healthcare Conference on Thursday, September 7, 2023 at 8:45 am (EDT) Morgan Stanley 21 st Annual Global Healthcare Conference on Monday, September 11, 2023 at 11:20 am (EDT) Bank of America 2023 Global Healthcare Conference on Thursday, September 14, 2023 at 8:15 am (BST) The presentations will be webcast live and can be accessed at Investor.Incyte.com...

Incyte (Nasdaq:INCY) today reports 2023 second quarter financial results, and provides a status update on the Company’s clinical development portfolio. "We delivered a strong quarter with total net product revenues growing 25% year over year led by double-digit Jakafi ® (ruxolitinib) growth and continued momentum from Opzelura ® (ruxolitinib) cream in atopic dermatitis and vitiligo in the United States," said Hervé Hoppenot, Chief Executive Officer, Incyte. "We continue to advance multiple...

Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor. This press release features multimedia. View the full release here:...

Incyte (Nasdaq:INCY) today announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura ® ) in children (age ≥2 to <12 years) with atopic dermatitis (AD). The study met its primary endpoint and showed significantly more patients treated with ruxolitinib cream 0.75% and 1.5% achieved Investigator’s Global Assessment Treatment Success (IGA-TS) than patients treated with vehicle...

Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 1, 2023. The schedule for the press release and conference call/webcast is as follows: Q2 2023 Press Release: August 1, 2023 at 7:00 a.m. ET Q2 2023 Conference Call: August 1, 2023 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13739925 If you are unable to...

Incyte Biosciences UK today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Opzelura ® (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. Opzelura is the first and only approved treatment in the United Kingdom (UK) to offer eligible patients with non-segmental vitiligo support for repigmentation. The MHRA decision follows the European...

Incyte (Nasdaq:INCY) annonce aujourd’hui que de multiples résumés contenant des données provenant de l’ensemble de son portefeuille d’oncologie seront présentés lors de la prochaine réunion annuelle 2023 de l’American Society of Clinical Oncology (ASCO) qui se tiendra du 2 au 6 juin à Chicago, et lors du congrès hybride 2023 de l’Association européenne d’hématologie (EHA2023) qui se tiendra à Francfort, en Allemagne, du 8 au 11 juin et virtuellement les 14 et 15 juin. «...

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting held June 2-6 in Chicago, and at the European Hematology Association 2023 (EHA2023) Hybrid Congress held in Frankfurt, Germany, from June 8-11 and virtually from June 14-15. “Our presence at ASCO and EHA illustrates Incyte’s ongoing commitment to science that can lead to additional,...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: William Blair 43 rd Annual Growth Stock Conference on Tuesday, June 6, 2023 at 11:20 a.m. (CDT) Goldman Sachs 44 th Annual Global Healthcare Conference on Monday, June 12, 2023 at 8:40 a.m. (PDT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based,...

Incyte (Nasdaq:INCY) today announced the creation of a new leadership role, appointing Pablo J. Cagnoni, M.D. President and Head of Research & Development (R&D) effective June 5, 2023. In this role and as a member of the Executive Team, Dr. Cagnoni will lead Incyte’s R&D efforts across its portfolio of programs in Oncology, Hematology and Inflammation and Autoimmunity including Dermatology. “This newly created role integrates chemistry, biology and development with the goal of maximizing the...

Incyte (Nasdaq:INCY) today reports 2023 first quarter financial results, and provides a status update on the Company’s clinical development portfolio. "Our first quarter results demonstrate continued year-over-year double-digit revenue growth driven by Jakafi, which grew across all indications, and Opzelura, which is on track to become one of the most successful dermatology launches in recent years. In addition, we further expanded our commercial portfolio with several regulatory approvals...

Incyte (Nasdaq:INCY) today announced new data from the Phase 2 SCRATCH-AD trial evaluating the short-term clinical benefits of Opzelura ® (ruxolitinib) cream 1.5% to control pruritus (itching) and reduce disease severity in adult patients with atopic dermatitis (AD), the most common type of eczema. These data were featured in a poster presentation (Poster #396) at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washington, D.C. Results showed that patients...

Incyte (Nasdaq:INCY) a annoncé aujourd'hui que la Commission européenne (CE) a accordé une autorisation de mise sur le marché pour la crème Opzelura ® (ruxolitinib) 15 mg/g dans le traitement du vitiligo non segmentaire avec atteinte du visage chez l'adultes et l'adolescent à partir de 12 ans. Opzelura est le premier et le seul traitement approuvé dans l'UE à offrir un soutien à la repigmentation chez des patients éligibles atteints de vitiligo non segmentaire, une maladie auto-immune...

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has granted a marketing authorization for Opzelura ® (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. Opzelura is the first and only approved treatment in the European Union (EU) to offer support for repigmentation in eligible patients with non-segmental vitiligo, a chronic autoimmune disease characterized by depigmentation of skin...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY PR Newswire NEW YORK, April 19, 2023 NEW YORK , April 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Incyte Corporation ("Incyte" or the "Company") (NASDAQ: INCY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Incyte and certain of its officers...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: Bank of America 2023 Health Care Conference on Wednesday, May 10, 2023 at 10:40 a.m. (PDT) 2023 RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023 at 10:30 a.m. (EDT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte Incyte is a Wilmington, Delaware-based, global...

MorphoSys U.S. Inc., eine hundertprozentige Tochtergesellschaft der MorphoSys AG (FSE: MOR; NASDAQ: MOR) und Incyte (Nasdaq: INCY), haben heute die abschließenden Fünf-Jahres-Nachbeobachtungsdaten der Phase-2-Studie L-MIND vorgelegt, die zeigen, dass Monjuvi ® (Tafasitamab-cxix) plus Lenalidomid, gefolgt von einer Monotherapie mit Monjuvi, bei erwachsenen Patienten mit rezidiviertem oder refraktärem diffusem großzelligem B-Zell-Lymphom (DLBCL) ein verlängertes, dauerhaftes Ansprechen...

MorphoSys U.S. Inc., une filiale à part entière de MorphoSys AG (FSE : MOR ; NASDAQ : MOR), et Incyte (Nasdaq : INCY) ont annoncé aujourd’hui les dernières données de suivi sur cinq ans de l’étude L-MIND de phase 2 montrant que la combinaison de Monjuvi ® (tafasitamab-cxix) et de lénalidomide suivie d’une monothérapie par Monjuvi a fourni des réponses prolongées et durables chez les patients adultes atteints d’un lymphome diffus à grandes cellules B (LDGCB) récidivant ou...

MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (Nasdaq: INCY) today announced final five-year follow-up data from the Phase 2 L-MIND study showing that Monjuvi ® (tafasitamab-cxix) plus lenalidomide followed by Monjuvi monotherapy provided prolonged, durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). These data were featured as a late-breaking oral presentation (Abstract # CT022) at the...